ARMP Armata Pharmaceuticals, Inc.
$3.52▲ +1.97%
Healthcare
Other
Volume 3.2K
Avg Volume (10D) 117.5K
Key Metrics & Fundamentals
Market Cap
$130.81M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.75 - 14.98
% vs 50 MA
-19.55%
% vs 200 MA
-51.25%
RSI-14
46.3
MACD Histogram
+0.0700
Beta (1Y vs SPY)
0.67
Free Cash Flow
-$5.85M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$109.33M
COGS
–
Operating Exp
$8.79M
Operating Income
-$8.79M
EBIT
-$8.79M
Pretax Income
-$115.35M
Net Income
-$115.35M
EPS (Diluted)
-3.16
Price & Volume History
Loading chart…
Recent News
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
PR Newswire · Oct 7, 2026 7:00 AM ET
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
PR Newswire · Sep 23, 2026 7:00 AM ET
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
PR Newswire · Sep 21, 2026 7:00 AM ET
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
InvestorsHub · Sep 14, 2026 9:34 AM ET
Armata Pharmaceuticals' AP-SA02 Gets FDA Breakthrough Therapy Designation
MT Newswires · Sep 14, 2026 7:47 AM ET
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
PR Newswire · Sep 14, 2026 7:00 AM ET
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · Sep 10, 2026 7:00 AM ET
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
PR Newswire · Sep 3, 2026 7:00 AM ET
Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
PR Newswire · Aug 13, 2026 10:31 AM ET
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
PR Newswire · Aug 12, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ARMP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.